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Renal outcome of type 2 diabetes in South Africa — 
a 12-year follow-up study
G R Keeton, R van Zyl Smit, A Bryer
Aims. Previous studies of type 2 diabetes mellitus have
indicated a benign renal outcome after long-term follow-up.
The aim of this study was to determine how often renal
failure due to diabetic nephropathy was a cause of death in
patients with type 2 diabetes.
Methods. Prospective observational study of 59 South African
patients with type 2 diabetes over a 12-year period.  During
the study repeated clinical evaluations were accompanied by
measurements of serum creatinine, serum cholesterol, random
blood sugar, and urine protein/creatinine ratios.
Results. The mean duration of diabetes at the end of the study
was 17.8 years. There was a wide variation in the time from
clinical diagnosis of diabetes to macroproteinuria (mean 9.7
years, SD 5.9, range 0 - 21) and the rate of deterioration of
renal function.  This rate correlated with poor control of blood
pressure, a glucose level of > 14 mmol/l, heavy proteinuria, a
high retinopathy score, a body mass index of < 28 and the
number of pack years of smoking.
At the end of the study 47 patients (79.7%) had died.  Of
these deaths 17 (28.8%) were due to chronic renal failure.
Conclusions. In contrast to other studies we have shown that
in a developing country renal failure in type 2 diabetic
patients is a major cause of death.  Determining the prognosis
for an individual patient is difficult as there are wide ranges
in the time of onset of proteinuria, the rise in serum creatinine
and the time to ultimate progression to end-stage renal
failure.
S Afr Med J 2004; 94: 771-775.
There are few long-term follow-up studies evaluating renal
prognosis in type 2 diabetes.  In 1982 Fabré et al.1 reported
minimal renal impairment with almost no deaths due to
chronic renal failure in type 2 diabetic patients after 0 - 35 years
of follow-up.1 As our experience of type 2 diabetes in a
developing country did not match these results we undertook a
prospective observational long-term follow-up study to
evaluate the natural history of type 2 diabetes.  
Methods
Inclusion criteria
Our inclusion criteria were similar to those of other groups
who distinguished type 2 from type I diabetics.2-4
Macroproteinuria at entry was assessed with a reactive test
tape (Multistix; Ames, Elkhart, IN) on two consecutive urine
samples.5,6
Patient recruitment and methods
Patients were recruited sequentially from the Groote Schuur
Hospital Outpatients Diabetic Clinic or the Somerset Hospital
Outpatients and were evaluated every 2 - 3 years over a period
of 12 years.  Patients were informed that they would be
examined and that their blood and urine would be tested but
that routine care would continue under their primary care
physicians.  
The following were documented at each visit: the age at
onset of diabetes; the date and age at which insulin was
started; the time from the onset of diabetes to the first recorded
macroproteinuria; the time to the rise in serum creatinine (SCr);
the time to the doubling of the SCr; and the time from
doubling to an SCr level of 400 µmol/l and to end-stage renal
failure (ESRF).  
A detailed retrospective analysis was made of patient records
dating back to 1966. Evidence for ischaemic heart disease
(IHD), peripheral vascular disease (PVD), cerebrovascular
disease (CVD) and any symptoms relating to cardiac
decompensation were noted.
Blood pressure was measured with a mercury
sphygmomanometer after a 5-minute rest period.  Retinopathy
was carefully documented by the primary investigator and
virtually all patients were also seen by the specialist
Ophthalmology Clinic.3,5 The patient’s height and weight were
recorded at entry and at follow-up visits to evaluate the body
mass index (BMI). 
Criteria
Hypertension was defined by three successive diastolic blood
pressure readings of 90 mmHg or greater.  IHD was defined by
a typical history of angina, ECG evidence of a previous
Department of Medicine, Faculty of Health Sciences, University of Cape Town,
South Africa
G R Keeton, FCP (SA), MRCP, FRCP
R van Zyl Smit, FCP (SA), FRCP, MD
A Bryer, FCP (SA), PhD, MMed (Neurol)
772
September 2004, Vol. 94, No. 9  SAMJ
ORIGINAL ARTICLES
myocardial infarction or chest pain associated with an elevated
creatine phosphokinase level.  PVD was defined by a typical
history of claudication and the absence of peripheral pulses.
The final cause of death was established in all but 2 patients
by death certificate together with direct contact with the doctor,
family member or hospital staff caring for the patient.  If death
due to renal failure was complicated by a co-morbid condition
such as cardiomyopathy or sepsis, an SCr of 500 µmol/l or
more was defined as primary renal death.
The grading of adverse factors
Adverse factors were graded as:  retinopathy: 1 = no diabetic
retinopathy, 2 = mild background changes, 3 = severe
background retinopathy; 4 = proliferative retinopathy;  IHD: 1
= absent, 2 = angina, 3 = myocardial infarction;  vascular
disease: 1 = no vascular disease, 2 = CVD, 3 = PVD and 4 =
CVD and PVD;  alcohol use: 1 = no intake, 2 = occasional social
drinking,  3 = moderate regular intake, and 4 = heavy intake
affecting and interfering with lifestyle and health;  peripheral
neuropathy: 1= no peripheral neuropathy, 2 = asymptomatic,  3
= symptomatic with objective findings of absent or reduced
ankle reflexes and/or distal sensation.
Patients were divided into four groups according to the SCr
level at the end of the study or death.  Group 1 had a normal
SCr throughout,  group 2 levels between 120 and 199 µmol/l,
group 3 levels between 200 and 399 µmol/l,  and group 4 levels
of 400 µmol/l or more.
Laboratory investigations
At each visit urea, SCr, cholesterol and blood glucose were
measured and a random urine sample tested for
protein/creatinine ratio.7
Statistical evaluation
Comparisons were made between males and females;  insulin-
dependent and non-insulin-dependent patients;  smokers and
non-smokers;  patients alive at the end of the study and those
who had died of ESRF by the end of study;  patients with an
SCr rise soon after the onset of diabetes and those with a later
rise;  patients with preserved renal function (groups 1 and 2) as
against poor renal function (groups 3 and 4, and group 4
alone);  group 4 patients who died early and those who died
later; and patients with rapid doubling of SCr and those with
slow doubling.
Factors that were compared by Student’s t-tests in all these
groups were:  age at the onset of clinical diabetes (ONSET);
duration of diabetes;  age at the end of the study or death;
smokers versus non-smokers by ‘pack-years’ (20 cigarettes/day
x 1 year = 1 pack-year);  insulin-dependent versus non-insulin-
dependent patients;  BMI < 28 or > 27;  systolic and diastolic
blood pressure;  blood glucose;  serum cholesterol;  and the
times from onset of diabetes to macroproteinuria,  to the initial
rise of SCr, to doubling of SCr, and to SCr reaching ≥ 400
µmol/l.  Chi-square analysis was applied to the non-
continuous graded variables of CVD/PVD, IHD, retinopathy
and BMI.  
All calculations were made with a commercially available
program (Statgraphics;  STSC, Rockville, MD, USA).8
Results
Of 62 individuals entered into the study, 3 were lost to follow-
up.  The mean age at entry was 62 years.  There were 21 males
and 38 females.  Of the patients 44 were of mixed ancestry, 9
black, 5 white and 1 Indian.  The mean duration of diabetes
was 17.8 years.  Twenty-seven patients were on diet or oral
hypoglycaemic agents and 32 patients required insulin.  The
mean BMI was 31 (SD 6), the median 31 and the range 19 - 46.
Thirty-two patients were non-smokers and 27 smokers.  Six
patients admitted to substantial intake of alcohol in the past
but 5 had stopped many years before the onset of diabetes and
only 1 patient continued major alcohol abuse.
The significant differences between patients on insulin and
those on oral agents were a longer duration of diabetes (19.5 v.
15.8 years, p < 0.024), a longer time before doubling of SCr (17.7
v. 13.7 years, p < 0.04) and poorer control of blood glucose (14.1
v. 12.3, p < 0.005) in patients on insulin.
Comparing patients with good renal function (groups 1 and
2) and those with poorest renal function (group 4), group 4 had
higher diastolic blood pressures (96 v. 90 mmHg, p < 0.022),
higher protein/Cr ratios (5.9 v. 2.9, p < 0.0006) and a higher SCr
at entry (115 v. 84.7 µmol/l, p < 0.0027) with a shorter time to
doubling of SCr (14.4 v. 20.2 years, p < 0.015).
Chi-square analysis of the graded risk factors, comparing
patients with good renal function (groups 1 and 2) to group 4,
showed group 4 to have higher scores for vascular disease
(CVA/PVD p < 0.04), retinopathy (p < 0.002) and glucose > 14
mmol/l (p < 0.035).
Table I illustrates the pattern of renal dysfunction and the
time to events.  There was a wide range for onset of proteinuria
with even macroproteinuria at first diagnosis of diabetes.
Eighty-three per cent of patients (49/59) had an elevated SCr at
the end of the study and in 66.1% (39/59) the SCr level had
doubled during the study.  
The data for 4 patients listed in Fig. 1 illustrate the wide
variability in the duration of proteinuria and the deterioration
of renal function. Patient 1 had prolonged proteinuria with a
minimal fall-off in renal function,  patient 2 had impaired renal
function at entry with a slow decline to an SCr of 600 µmol/l,
and patients 3 and 4 had macroproteinuria from 14 to 17 years
before reaching ESRF.
By the end of study 47 of the 59 patients had died and in
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only 2 patients was the cause of death not established.  Death
(at a mean age of 65 years) was due to chronic renal failure in
17 cases, myocardial infarction (MI) in 11 and CVA in 7.
Patients who had died from chronic renal failure were more
likely to have had a high entry SCr (p <  0.006), a BMI of < 28 (p
< 0.003), more severe retinopathy (p< 0.002) and a mean
glucose level of >14 mmol/l (p < 0.035) compared with the
patients who were still alive at follow-up.  The differences
between patients who died at > 73 years of age compared with
those who died below the age of 60 years are shown in 
Table II.  The younger age at death is partially explained by the
earlier age of onset of diabetes.  
Table III shows the differences between smokers and non-
smokers with any degree of impaired renal function (groups 2,
3 and 4).  
Discussion
When this study was initiated in 1984 there was little
documentation of diabetic nephropathy as a cause of ESRF in
type 2 diabetics.  At the end of the present study we were able
to confirm that ESRF was a major cause of death in 29% of our
mainly non-Caucasian patients (17/59).   In studies of largely
Caucasian patients with type 2 diabetes death due to chronic
Table I. Pattern of renal functional deterioration to end of study or death
Age (yrs)
N Mean (SD) Median Range
Age at entry to study 59 62    (9.4) 62 46 - 89
Age of onset of diabetes 59 47    (10) 46 28 - 81
Duration of diabetes 59 17.8 (6) 17.0 4 - 33
Duration of diabetes to proteinuria 56 9.7   (5.9) 9.0 0 - 21
Initial rise in SCr 40 13.5 (5.2) 13.5 0 - 25
Creatinine rise to doubling 39 16.4 (5.6) 16.0 3 - 28
Doubling of SCr to level of 400 µmol/l 24 17.0 (6) 18.0 3 - 31
Age at 1995 or death 58 65    (9) 63.0 48 - 91
Years 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Patient 83 98 104 115 104 81 100 131 120 132 139 Cr
1 + ++ ++ ++ ++ ++ ++ +++ Pr
Age 48 Average BP 150/90 Alive age 63
Comment: proteinuria for13 years with minimal fall off in function
Years 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Patient 200 263 310 332 396 442 422 600 Cr
2 +++ +++ +++ +++ Pr
Age 61 Average BP 190/100 Died age 77
Comment: entry creatinine 200 and proteinuria for9 years -yet 9 years to ESRF
Years 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Patient 124 113 130 140 167 172 145 149 148 200 152 280 457 640 1455 Cr
3 +++ +++ +++ +++ ++ ++ +++ +++ ++++ ++++ ++++ ++++ +++ +++ ++ Pr
Age 50 Average BP 170/110 Died age 68
Comment: Creatinine rise and proteinuria for17 years (from initial diagnosis)
Years 0 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Patient 12 years 107 106 118 177 150 150 220 350 405 357 342 458 666 1142 Cr
4 ++ ++ +++ ++ ++ ++ ++++ ++++ ++ ++ ++ +++ +++ Pr
Age 40 Average BP 155/90 Died age 68
Comment: Proteinuria for14 years before ESRF
Fig. 1.  Variability in duration and magnitude of proteinuria and the rate of deterioration of renal function in 4 patients for comparison with the
average shown in Table I.
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renal failure (CRF) is rare, with reports of no deaths1,9 and 
3 - 8% of deaths due to CRF.10,11 There is a high incidence of
ESRF due to type 2 diabetes in Australian aboriginals (42%)
and New Zealand Maoris (61%),12 and a higher relative risk
(4.8) among black Americans.13
The reason why our cohort of patients showed a wide
variation in the evolution of nephropathy may include some of
the following factors: imprecise clinical timing of the onset of
type 2 diabetes; vascular and cardiac deaths interrupting the
natural progression of renal failure; non-diabetic renal disease
(NDRD) in some patients; variations in the incidence and
progression of nephropathy in different racial groups; possible
effect of male or female gender; and the impact of blood
pressure control and appropriate therapy on the rate of
progression.
Difficulty in defining the precise time of onset of type 2
diabetes has been documented by Fabré et al.,1 who were
uncertain of the time of onset in 20 out of 490 of their patients,
and is supported by the presence of macroproteinuria in 5 of
our patients at the time of apparent onset of clinical diabetes.
In two large population studies of the prevalence of
retinopathy the onset of  retinopathy was predicted to be 4 - 7
years before the clinical diagnosis of diabetes,4 while the
chemical diagnosis of diabetes can precede retinopathy by
5 - 40 years.14 The delay between the biochemical onset of
diabetes and its clinical diagnosis can therefore be very difficult
to determine with certainty. 
Vascular and cardiac death interrupted the natural evolution
to renal failure in 6 of our group 3 patients.  In three studies of
largely Caucasian patients from the UK, Israel and Denmark,
the major cause of death was vascular with only 0 - 3% of
deaths due to uraemia.9,10
In our study neither renal biopsy nor postmortem histology
was available to confirm diabetic nephropathy as a cause of the
chronic renal failure.  In the few studies where renal biopsies
were available the percentages of NDRD ranged from 9% to
28%.1,15,16 The higher figure reflects selective referrals, and in
black patients the incidence was only 5.9%.  Factors suggesting
NDRD were age of onset > 55 years, duration of diabetes < 5
years, no neuropathy and Caucasian race.  All these features
were minimally represented in our patients. 
Various interstitial and vascular changes have been
interpreted as NDRD in diabetic patients, yet interstitial and
vascular changes as a feature of early diabetic nephropathy are
provided from biopsy data of 53 consecutive type 2 diabetic
patients with micro-albuminuria.17
Cigarette smoking is a well-known adverse factor in diabetic
patients, with a higher percentage developing micro-
albuminuria11 and macroproteinuria.18 In our smokers the onset
of proteinuria was earlier and death occured at a younger age
(Table III) than non-smokers, who had a higher systolic blood
pressure and more severe retinopathy. 
While the small number of patients in our study does not
allow major conclusions in relation to the effects of
hypertension, an elevated diastolic blood pressure was
associated with severely impaired renal function and a younger
age at death (Table II). Higher systolic blood pressures were
found in the non-smokers who lived longer (Table III).  
The association of poor glucose control with complications of
diabetes is well established.11,18,19 We only found an association
between random blood sugar and poor renal function at a
glucose level > 14 mmol/l.  In patients with micro-albuminuria
and an HbA1c > 8.1% the risk of retinopathy increases
logarithmically.  Below these levels the relationship is flat.20
A strong association of retinopathy with macroproteinuria,3,5
fatal myocardial infarction,2 PVD and peripheral neuropathy5
has been shown.  In our patients, retinopathy was associated
with poor renal function and death from chronic renal failure
(association of retinopathy score and renal function p < 0.002).  
The association of a BMI < 28 in our patients with impaired
renal function is difficult to explain since they do not belong to
the late-onset version of type 1 diabetes as only 5 of 10 were on
insulin.  An adverse factor in these 10 patients was a mean
glucose level of > 13.8 mmol/l.  An apparent adverse effect of a
low BMI on renal function is also suggested by a study on type
2 patients not on insulin, in whom proteinuria was present in
16.8% with a BMI of 25.2 - 28.4 as opposed to 7.9% with a BMI
of 32 - 49.3 after 4-year follow-up.18
Table II.  Significant differences between patients dying at > 73
years of age compared to those dying < 60 years of age (mean (SD))
Age at death
> 73 years < 60 years 
(N = 9) (N = 12) p-value
Pack-years smoking 3.1  (4) 23.3 (28) < 0.045
Age at onset of diabetes 59  (11) 42     (7) < 0.0003
Maximal proteinuria 2.9  (1) 6.1    (4) < 0.035
Diastolic blood pressure 86   (8) 97    (11) < 0.03
Table III.  Comparison between smokers and non-smokers with
impaired renal function (SCr > 119 µmol/l) in 1995*
Smokers Non-smokers 
(N = 24) (N = 25) p-value
Age at 1995 or
death (yrs) 62    (8) 68     (9) < 0.016
Systolic blood 
pressure (mmHg) 158  (15) 167  (15) < 0.049
Retinopathy score 1.87 (0.9) 2.54 (0.9) < 0.017
Onset of proteinuria (yrs) 8.7   (6) 12.1 (5) < 0.045
*Five of 24 smokers were alive at a mean age of 63 years and 3 of 25 non-smokers
were alive at a mean age of 67 years.
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Conclusions
In contrast to other studies, we have shown that renal failure is
a major cause of death in type 2 diabetics in a developing
country, particularly among non-Caucasians.  This study was
started before angiotensin-converting enzyme (ACE) inhibitors
were commonly used and therefore provides information on
the natural progression of diabetic nephropathy.
Determining the prognosis for an individual patient is
difficult as there is a wide range for time of onset of
proteinuria, rise in SCr and ultimate progression to renal
failure.  We have shown a strong association between
retinopathy, heavy proteinuria and an adverse renal outcome.
A further major adverse factor in our study is heavy smoking,
which was associated with a younger age at death, earlier
onset and heavier proteinuria.  The importance of vascular
disease as a cause of death in a small number of patients was
shown by the interruption of the progression to ESRF by
vascular events.
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Mitochondrial function deficiency link to type 2 diabetes
IN BRIEF
The authors of an article recently published in the New England Journal of Medicine (2004; 350: 664-671) state that insulin
resistance in the skeletal muscle of insulin-resistant offspring of patients with type 2 diabetes is associated with dysregulation
of intramyocellular fatty acid metabolism, possibly because of an inherited defect in mitochondrial oxidative phosphorylation.
The presence of similar inherited defects in beta-cell mitochondrial function or content might explain the increased
incidence of diabetes in the insulin-resistant offspring of patients with type 2 diabetes. This could lead to answers to a
number of questions regarding moderately overweight people who develop type 2 diabetes early in life, and also explain why
it does not develop in obese, inactive people. Efficacy of drug therapy may be enhanced with this new knowledge.The study
permits us ‘to peer into the powerhouse of the cell in order to bring causation and pathogenesis into sharper focus’.
